| Filed On | Filing |
|---|---|
| 01 Jun 2026 | TRANSACTION IN OWN SHARES |
| 01 Jun 2026 | TOTAL VOTING RIGHTS |
| 28 May 2026 | POSITIVE PHASE 3 DATA FOR BEPIROVIRSEN |
| 27 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 26 May 2026 | TRANSACTION IN OWN SHARES |
| 26 May 2026 | ADMISSION TO TRADING |
| 22 May 2026 | Q2 2026 RESULTS DATE CONFIRMED - 28 JULY 2026 |
| 20 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 20 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 19 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 18 May 2026 | TRANSACTION IN OWN SHARES |
| 18 May 2026 | JAPAN MHLW APPROVES AREXVY FOR ADULTS 18-49 AIR |
| 14 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 11 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 11 May 2026 | GSK - FINAL TRANCHE OF SHARE BUYBACK PROGRAMME |
| 11 May 2026 | COLLABORATION WITH CTTQ FOR BEPIROVIRSEN |
| 06 May 2026 | RESULT OF AGM |
| 05 May 2026 | DIRECTOR/PDMR SHAREHOLDING |
| 01 May 2026 | HOLDING(S) IN COMPANY |
| 01 May 2026 | TOTAL VOTING RIGHTS |
Loading...
